Featured NewsNovo Nordisk reveals obesity drug with up to 22 percent weight lossbasrahdaily.comJanuary 24, 2025January 24, 2025 January 24, 2025January 24, 2025 Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a...
BusinessNovo Nordisk tops Tesla in market value with new obesity pillbasrahdaily.comMarch 8, 2024March 8, 2024 March 8, 2024March 8, 2024 Novo Nordisk edges past Tesla in market value on successful obesity pill trial. Danish company's shares soar....